Titre : Molécules d'interaction stromale

Molécules d'interaction stromale : Questions médicales fréquentes

Termes MeSH sélectionnés :

General Practice

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une interaction stromale ?

Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales.
Biopsie Immunohistochimie
#2

Quels tests sont utilisés pour les molécules stromales ?

Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale.
Test ELISA Western Blot
#3

Les marqueurs stromaux sont-ils spécifiques ?

Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux.
Marqueurs tumoraux Tumeurs
#4

Peut-on détecter les molécules stromales par imagerie ?

Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales.
Imagerie par résonance magnétique Interactions cellulaires
#5

Quel rôle joue la biopsie dans le diagnostic ?

La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs.
Biopsie Analyse histologique

Symptômes 5

#1

Quels symptômes sont liés aux interactions stromales ?

Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale.
Douleur Inflammation
#2

Les interactions stromales causent-elles des symptômes ?

Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés.
Croissance tumorale Symptômes
#3

Comment les symptômes varient-ils selon les tumeurs ?

Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique.
Tumeurs Environnement tumoral
#4

Les symptômes sont-ils précoces ou tardifs ?

Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale.
Symptômes précoces Symptômes tardifs
#5

Les symptômes sont-ils réversibles ?

Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales.
Traitement Réversibilité des symptômes

Prévention 5

#1

Peut-on prévenir les interactions stromales ?

La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation.
Prévention Facteurs de risque
#2

Quels modes de vie aident à prévenir les tumeurs ?

Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques.
Mode de vie sain Prévention des tumeurs
#3

Les dépistages réguliers sont-ils utiles ?

Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales.
Dépistage Détection précoce
#4

L'éducation sur le cancer est-elle importante ?

Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer.
Éducation sur le cancer Sensibilisation
#5

Les vaccins peuvent-ils prévenir les tumeurs ?

Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés.
Vaccins Prévention du cancer

Traitements 5

#1

Quels traitements ciblent les molécules stromales ?

Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules.
Thérapies ciblées Immunothérapie
#2

Les traitements sont-ils efficaces ?

L'efficacité varie selon le type de tumeur et la nature des interactions stromales.
Efficacité des traitements Tumeurs
#3

Y a-t-il des effets secondaires des traitements ?

Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires.
Effets secondaires Réactions immunitaires
#4

Comment les traitements sont-ils personnalisés ?

Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal.
Médecine personnalisée Profil moléculaire
#5

Les traitements sont-ils combinés ?

Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité.
Thérapies combinées Efficacité des traitements

Complications 5

#1

Quelles complications peuvent survenir ?

Les complications incluent la progression tumorale, la résistance au traitement et la métastase.
Complications Métastase
#2

Les interactions stromales aggravent-elles les complications ?

Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement.
Progression tumorale Complications
#3

Comment gérer les complications ?

La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies.
Gestion des complications Suivi médical
#4

Les complications sont-elles prévisibles ?

Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions.
Prévisibilité Interactions tumorales
#5

Les complications affectent-elles la qualité de vie ?

Oui, les complications peuvent significativement impacter la qualité de vie des patients.
Qualité de vie Complications

Facteurs de risque 5

#1

Quels sont les facteurs de risque des interactions stromales ?

Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques.
Facteurs de risque Inflammation chronique
#2

L'alimentation influence-t-elle les risques ?

Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales.
Alimentation Antioxydants
#3

Le stress est-il un facteur de risque ?

Le stress chronique peut influencer l'inflammation et augmenter le risque de complications.
Stress Inflammation
#4

Les antécédents familiaux jouent-ils un rôle ?

Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales.
Antécédents familiaux Prédisposition génétique
#5

L'exposition à des toxines est-elle un risque ?

Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer.
Toxines Exposition environnementale
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Molécules d'interaction stromale : Questions médicales les plus fréquentes", "headline": "Molécules d'interaction stromale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Molécules d'interaction stromale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines membranaires", "url": "https://questionsmedicales.fr/mesh/D008565", "about": { "@type": "MedicalCondition", "name": "Protéines membranaires", "code": { "@type": "MedicalCode", "code": "D008565", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Molécule-1 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 1", "url": "https://questionsmedicales.fr/mesh/D000071737", "about": { "@type": "MedicalCondition", "name": "Molécule-1 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071737", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.500" } } }, { "@type": "MedicalWebPage", "name": "Molécule-2 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 2", "url": "https://questionsmedicales.fr/mesh/D000071738", "about": { "@type": "MedicalCondition", "name": "Molécule-2 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071738", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale", "alternateName": "Stromal Interaction Molecules", "code": { "@type": "MedicalCode", "code": "D000071736", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Peter B Stathopulos", "url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca." } }, { "@type": "Person", "name": "Paul Sohn", "url": "https://questionsmedicales.fr/author/Paul%20Sohn", "affiliation": { "@type": "Organization", "name": "Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Wenting Wu", "url": "https://questionsmedicales.fr/author/Wenting%20Wu", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Marjan Slak Rupnik", "url": "https://questionsmedicales.fr/author/Marjan%20Slak%20Rupnik", "affiliation": { "@type": "Organization", "name": "Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Chih-Chun Lee", "url": "https://questionsmedicales.fr/author/Chih-Chun%20Lee", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "[Care of dementia in the general practice].", "datePublished": "2023-08-13", "url": "https://questionsmedicales.fr/article/37573556", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1556/650.2023.32816" } }, { "@type": "ScholarlyArticle", "name": "An exploration of Northern Ireland general practice pharmacists' views on their role in general practice: a cross-sectional survey.", "datePublished": "2024-06-06", "url": "https://questionsmedicales.fr/article/38844848", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12875-024-02457-7" } }, { "@type": "ScholarlyArticle", "name": "Continuity of care in general practice in Norway.", "datePublished": "2024-07-11", "url": "https://questionsmedicales.fr/article/38991043", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0305164" } }, { "@type": "ScholarlyArticle", "name": "Tailoring communication practices to support effective delivery of telehealth in general practice.", "datePublished": "2024-06-27", "url": "https://questionsmedicales.fr/article/38937674", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12875-024-02441-1" } }, { "@type": "ScholarlyArticle", "name": "[Prostatic hyperplasia: Evaluation of practices in general practice, dissemination, and impact of recommendations].", "datePublished": "2022-07-13", "url": "https://questionsmedicales.fr/article/35842333", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.purol.2022.06.001" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Molécules d'interaction stromale", "item": "https://questionsmedicales.fr/mesh/D000071736" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Molécules d'interaction stromale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Molécules d'interaction stromale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Molécules d'interaction stromale", "description": "Comment diagnostiquer une interaction stromale ?\nQuels tests sont utilisés pour les molécules stromales ?\nLes marqueurs stromaux sont-ils spécifiques ?\nPeut-on détecter les molécules stromales par imagerie ?\nQuel rôle joue la biopsie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Molécules d'interaction stromale", "description": "Quels symptômes sont liés aux interactions stromales ?\nLes interactions stromales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les tumeurs ?\nLes symptômes sont-ils précoces ou tardifs ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Molécules d'interaction stromale", "description": "Peut-on prévenir les interactions stromales ?\nQuels modes de vie aident à prévenir les tumeurs ?\nLes dépistages réguliers sont-ils utiles ?\nL'éducation sur le cancer est-elle importante ?\nLes vaccins peuvent-ils prévenir les tumeurs ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Molécules d'interaction stromale", "description": "Quels traitements ciblent les molécules stromales ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires des traitements ?\nComment les traitements sont-ils personnalisés ?\nLes traitements sont-ils combinés ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Molécules d'interaction stromale", "description": "Quelles complications peuvent survenir ?\nLes interactions stromales aggravent-elles les complications ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Molécules d'interaction stromale", "description": "Quels sont les facteurs de risque des interactions stromales ?\nL'alimentation influence-t-elle les risques ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un risque ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=General+Practice#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une interaction stromale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les molécules stromales ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale." } }, { "@type": "Question", "name": "Les marqueurs stromaux sont-ils spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux." } }, { "@type": "Question", "name": "Peut-on détecter les molécules stromales par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux interactions stromales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale." } }, { "@type": "Question", "name": "Les interactions stromales causent-elles des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les tumeurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique." } }, { "@type": "Question", "name": "Les symptômes sont-ils précoces ou tardifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales." } }, { "@type": "Question", "name": "Peut-on prévenir les interactions stromales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation." } }, { "@type": "Question", "name": "Quels modes de vie aident à prévenir les tumeurs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales." } }, { "@type": "Question", "name": "L'éducation sur le cancer est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les tumeurs ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés." } }, { "@type": "Question", "name": "Quels traitements ciblent les molécules stromales ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie selon le type de tumeur et la nature des interactions stromales." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires." } }, { "@type": "Question", "name": "Comment les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal." } }, { "@type": "Question", "name": "Les traitements sont-ils combinés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la progression tumorale, la résistance au traitement et la métastase." } }, { "@type": "Question", "name": "Les interactions stromales aggravent-elles les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque des interactions stromales ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer l'inflammation et augmenter le risque de complications." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 02/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Peter B Stathopulos

4 publications dans cette catégorie

Affiliations :
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca.

Paul Sohn

3 publications dans cette catégorie

Affiliations :
  • Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.

Wenting Wu

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.

Marjan Slak Rupnik

3 publications dans cette catégorie

Affiliations :
  • Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Institute of Physiology, Faculty of Medicine, University of Maribor, Maribor, Slovenia.

Chih-Chun Lee

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.

Tatsuyoshi Kono

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.

Carmella Evans-Molina

3 publications dans cette catégorie

Affiliations :
  • Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.
  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Mitsuhiko Ikura

2 publications dans cette catégorie

Affiliations :
  • Department of Medical Biophysics, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada. Electronic address: mikura@uhnresearch.ca.

Matthew J Novello

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario N6A5C1, Canada.

Seung Yeon Jeong

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Jun Hee Choi

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Eun Hui Lee

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Junyang Liu

2 publications dans cette catégorie

Affiliations :
  • Xiamen University, College of Chemistry and Chemical Engineering & Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), CHINA.

Wenjing Hong

2 publications dans cette catégorie

Affiliations :
  • Xiamen University, College of Chemistry and Chemical Engineering, Siming south road 422, 3012, Xiamen, CHINA.

Farooq Syed

2 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Staci A Weaver

2 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Garrick Chang

2 publications dans cette catégorie

Affiliations :
  • Department of Physics, Indiana University Indianapolis, Indianpolis, Indiana, USA.

Jing Liu

2 publications dans cette catégorie

Affiliations :
  • Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana, USA.

Eman Salem Algariri

1 publication dans cette catégorie

Affiliations :
  • Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
  • Hadhramout University, Faculty of Medicine and Health Sciences, Department of Basic Medical Sciences, Hadhramout, Yemen
Publications dans "Molécules d'interaction stromale" :

Rabiatul Basria S M N Mydin

1 publication dans cette catégorie

Affiliations :
  • Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
Publications dans "Molécules d'interaction stromale" :

Sources (10000 au total)

An exploration of Northern Ireland general practice pharmacists' views on their role in general practice: a cross-sectional survey.

There is limited research examining the views of general practice pharmacists (GPPs) on their role and their impact in general practice. The aim of this study was to explore GPPs' views regarding this... A paper-based self-administered questionnaire was mailed to 319 general practices in NI in 2022, directed to the GPP who spent most time at the practice. A variety of closed and open questions were in... 155 responses were received equating to a response rate of 48.5%. Most participants (72.3%) were female, independent prescribers (71%), and 64.5% were currently using their independent prescriber qual... The findings indicated that GPPs had largely positive views about their role and their impact on primary care. The results may be helpful for practices and service commissioners. Further research is n...

Continuity of care in general practice in Norway.

Maintaining continuity of care between doctors and patients is considered a fundamental aspect of quality in primary healthcare. In this study, we aim to examine continuity in Norway over time by comp... We employ individual-level data, which covers all primary care consultations. This data includes the identities of each patient and physician, and we can identify each patient's regular general practi... Our findings reveal that, at the national level, SLICC and UPC exhibit remarkable stability, reaching 64 and 71 percent, respectively, in 2021. However, there is significant geographical variation, wi... Our results demonstrate a high degree of continuity that has been stable over time. However, large geographical variations suggest that policymakers should strive to reduce geographical disparities in...

Tailoring communication practices to support effective delivery of telehealth in general practice.

The unprecedented increase in telehealth use due to COVID-19 has changed general practitioners' (GP) and patients' engagement in healthcare. There is limited specific advice for effective communicatio... This study involved recording telehealth consultations (n = 42), conducting patient surveys (n = 153), and interviewing patients (n = 9) and GPs (n = 15). These were examined using interaction analyti... Three key themes relating to communication in telehealth were identified across the different analyses. These were relationship building, conversational flow, and safety netting. The draft best practi... Effective communication is supported through relationship building and attention to conversational flow in telehealth consultations, which in turn allows for safety netting to occur. In telehealth, GP...

[Prostatic hyperplasia: Evaluation of practices in general practice, dissemination, and impact of recommendations].

In 2015, the French Association of Urology, by the male lower urinary tract symptoms Committee, published a practices guideline for the management of prostatic hyperplasia in general practice. Five ye... A specially designed questionnaire was distributed online via the departmental councils of the order and to all regional unions of liberal doctors. The distribution to general practitioners was at the... Two hundred and eighty responses were collected. Fifty-five percent of the population was female. 83 % of the general practitioners did not report having knowledge of the practice guideline. 77 % of d... The practices guideline for the management of prostatic hyperplasia in general practice proposed in 2015 by the male lower urinary tract symptoms Committee seems to be little known by general practiti... 4, grade C....

General practitioners' perceptions of pharmacists working in general practice: a qualitative interview study.

Pharmacists in general practice have been shown to enhance patient care and are becoming increasingly prevalent worldwide. Yet, little is known about general practitioners' (GPs') perceptions of pharm... Semi-structured interviews were conducted with GPs practising in the Republic of Ireland between October and December 2021. Content analysis was used to identify the most relevant Theoretical Domains ... Fifteen GPs were interviewed. Five TDF domains were found to be most relevant in affecting pharmacist integration: (1) 'environmental context and resources' (space, government funding, information tec... This is the first qualitative interview study to focus on exploring GPs' perceptions of pharmacists working in general practice outside of private practice settings. It has provided a deeper understan...

The attitudes of general practices towards clinical research.

During the financial year 2021/2022, the PANORAMIC study utilised the primary care setting to provide vital research into oral antivirals for COVID-19, recruiting more than 26 000 participants. Alongs... To identify the barriers and challenges facing practices that reduce their likelihood of engaging in clinical research, as well as potential incentives and motivators that would support or encourage t... Various factors must be considered as contributing to these figures, such as funding, regional deprivation, and the workload and workforce crisis; however, very little literature exists regarding GPs'... Data collection to begin summer 2024.... Knowledge gained from these activities will help inform researchers and research organisations, such as the NIHR, to provide support and opportunities for GPs across England, ensuring that more of the...

Consultation frequency and general practitioners' and practices' characteristics.

High workloads generated by a few patients who consult very frequently can become huge burdens for general practitioners (GPs). Patient-related factors have been repeatedly associated with frequent co... Data came from the SPAM Prev (Swiss Primary Health Care Active Monitoring, Prevention in primary care) national, cross-sectional survey conducted in 2015-16, including 167 GPs and 1105 patients. GPs c... Negative associations with consultation frequency were found for females (Incidence Rate Ratio (IRR) 0.94, 95%CI [0.88-1.01]), less compliant patients (IRR 0.91, 95%CI [0.84-0.98]), high self-perceive... GPs' practices' characteristics, like patients', are predictive of patients' consultation frequency, but those associations' underlying mechanisms require further qualitative investigation. These new ...

Determinants of medical student's perception of general practice.

Enhancing the attractiveness of a career in general practice is a significant public health concern, given the current shortage in Belgium.... The objective of this study is to determine the factors that influence students' decisions to pursue a career in general practice and their perceptions of it.... This prospective study was conducted in May 2023. A questionnaire, based on existing literature, was distributed to final-year medical students. Quantitative data were analysed using descriptive and b... Out of the 142 participating students (response rate: 45%), 29.3% expressed a preference for general practice, while 70.7% opted for other specialties. These groups exhibited significant differences (... Perceptions of...